化疗联合免疫治疗与单纯化疗治疗中晚期非小细胞肺癌疗效分析

目的评价化疗联合免疫治疗中晚期非细胞肺癌的近期疗效．方法42例中晚期非小细胞肺癌患者被随机分为两组：化疗联合免疫治疗组，单纯化疗组．观察患者疗效、生存质量、毒性反应、TH1／TH2免疫指标的变化，另选20例健康体检者为对照组．结果化疗联合免疫治疗组和单纯化疗组的完全缓解率分别是40％和25％，经统计学处理有显著性差异（P〈0．05）．生活质量：化疗联合免疫治疗组与单纯手术组总提高率分别为82．0％，45．5％（P〈0．05）．TH1／TH2两组治疗前无明显差异，但均低于对照组（P〈0．05），治疗后化疗联合免疫治疗组较单纯化疗组有明显回升（P〈0．05）．两组治疗前T淋巴细胞亚群、B细胞、NK细胞含量比较无显著性差异，联合治疗组治疗后1月与治疗前比较。CD4^＋和CD4^＋／CD8^＋比值、NK细胞改善（P〈0．05），且优于单纯化疗组（P〈0．05）．结论化疗联合免疫治疗对中晚期非小细胞肺癌具有较好的疗效，使其完全缓解率和生活质量有了较大提高。免疫情况有所改善．

Clinical Trial on Effects of Chemotherapy Treatment Combined with CIK in Patients with Non- small Cell Lung Cancer

Objective To explore the effect of CIK with chemotherapy treatment in patients with non-small cell lung cancer.Methods 42 cases of non-small cell lung caner were divided into combination treatment group(chemotherapy CIK)(n=22) and chemotherapy group(n=20)for observation of life quality,TH1/ TH2,immunity indexes,and 20 cases of health checkup were chosen as control group.Results The improvement rate of life quality was 82.0% and 42.0% respectively in combination treatment group and chemotherapy group(P<0.05).There was no significant difference in TH1/ TH2,T-lymphocyte,and NK cell before treatment in both groups.CD4~ ,CD4~ /CD8~ ,and NK cell in combined with CIK group after 1 month treatment were improved,which was superior to chemotherapy group(P<0.05).Conclusion chemotherapy treatment combined with CIK can improve the life quality,TH1/ TH2,and immunity function of the patients with lung cancer